Compare Emerson Electric Co. (EMR) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs McKesson Corporation — how do they compare? Emerson Electric Co. trades at $160.52 (market cap $88.72B), while McKesson Corporation trades at $930.2 (market cap $108.46B). The key difference: McKesson Corporation is the larger of the two by market cap, and Emerson Electric Co. pays the higher dividend (1.4%). Which is the better fit depends on your goals — on Pluang, investors hold Emerson Electric Co. for 81 Days and McKesson Corporation for 74 Days on average.
| EMR | MCK | |
|---|---|---|
Market Cap | $88.72B | $108.46B |
Volume | 2,355,255 | 712,607 |
Sector | Industrials | Health |
52-Week High | $164.38 | $995.69 |
52-Week Low | $123.30 | $725.17 |
Typical Hold Time | 81 Days | 74 Days |
Enterprise Value | $99.80B | $115.00B |
Dividend Yield | 1.4% | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $159.22, down 1.34% today, with a bullish technical signal and strong analyst support. Recent quarters show consistent earnings beats, with Q2 2026 EPS of $1.71 exceeding the $1.68 estimate. Revenue growth is steady, projected at $18.6B for 2026, while profitability metrics like a 13.83% net margin and 12.81% ROE reflect operational strength. The stock faces resistance near $160, with support at $158.
Outlook remains positive given earnings momentum and a consensus price target of $165.90, implying ~4% upside. Risks include debt levels rising to 31.26% of assets in 2025 and macroeconomic pressures on industrial demand. Institutional sentiment is bullish, with 53% of analysts rating Buy.
McKesson (MCK) trades at $910.33, down 1.23% over 24 hours, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue grew to $359.05 billion in 2025, though net margins remain thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing growth visibility in pharmaceutical distribution.
The outlook remains positive given analyst consensus favoring Buy ratings (80.65%) and a price target of $956.43, implying ~5% upside. Risks include margin pressure from drug pricing dynamics and policy uncertainty, while institutional accumulation and solid cash flow generation support stability. Earnings momentum and strategic partnerships position MCK for sustained growth, though investors should monitor competitive and regulatory headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
